This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leyton, J. Articles by McNeish, I. A. Search for Related Content PubMed PubMed Citation Articles by Leyton, J. Articles by McNeish, I. A.

Quantifying the Activity of Adenoviral E1A CR2 Deletion Mutants Using Renilla Luciferase Bioluminescence and 3'-Deoxy-3'-[¹⁸F]Fluorothymidine Positron Emission Tomography Imaging

¹ Molecular Therapy and PET Oncology Research Group, Clinical Sciences Centre, Imperial College School of Medicine, and ² Cancer Research UK Molecular Oncology Unit, Barts and the London School of Medicine, London, United Kingdom

Requests for reprints: Iain McNeish, Cancer Research UK Molecular Oncology Unit, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom. Phone: 44-20-7014-0425; Fax: 44-20-7014-0431; E-mail: iain.mcneish{at}cancer.org.uk.

The adenoviral E1A CR2 mutant dl922-947 has potent activity in ovarian cancer. We have used Renilla luciferase bioluminescence imaging to monitor viral E1A expression and replication and [¹⁸F]fluorothymidine positron emission tomography ([¹⁸F]FLT-PET) to quantify the activity of dl922-947 in vivo. We created dlCR2 Ren, with the same E1A CR2 deletion as dl922-947 and the luciferase gene from Renilla reniformis downstream of E1. Light emitted from s.c. and i.p. IGROV1 ovarian carcinoma xenografts was measured following treatment with dlCR2 Ren. Mice bearing s.c. IGROV1 xenografts were injected with 2.96 to 3.7 MBq of [¹⁸F]FLT 48 and 168 hours following i.t. injection of dl922-947 or control virus Ad LM-X. The presence of Renilla luciferase in dlCR2 Ren did not reduce in vitro nor in vivo potency compared with dl922-947. Light emission correlated closely with E1A expression in vitro and peaked 48 hours after dlCR2 Ren injection in both s.c. and i.p. IGROV1 xenografts. It diminished by 168 hours in s.c. tumors but persisted for at least 2 weeks in i.p. models. Normalized tumor [¹⁸F]FLT uptake at 60 minutes (NUV₆₀), fractional retention, and area under radioactivity curve all decreased marginally 48 hours after dl922-947 treatment and significantly at 168 hours compared with controls. There was a close linear correlation between NUV₆₀ and both tumor proliferation (Ki67 labeling index) and thymidine kinase 1 expression. Renilla luciferase bioluminescence and [¹⁸F]FLT-PET imaging are capable of quantifying the activity and effectiveness of E1A CR2–deleted adenoviral mutants in ovarian cancer. (Cancer Res 2006; 66(18): 9178-85)

This article has been cited by other articles:

				J. Leyton, G. Smith, M. Lees, M. Perumal, Q.-d. Nguyen, F. I. Aigbirhio, O. Golovko, Q. He, P. Workman, and E. O. Aboagye Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901 Mol. Cancer Ther., September 1, 2008; 7(9): 3112 - 3121. [Abstract] [Full Text] [PDF]